文献速递血栓与止血

抗PF4抗体与抗凝药物在疫苗诱导的血栓性血小板减少症中的相互作用

The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia.
PubMed 文献 · Blood · 2022-01-01

研究采用体外血流模型及体外实验,分析肝素、达那肝素、磺达肝癸钠和阿加曲班与VITT抗体/PF4复合物的相互作用。结果显示VITT IgG较健康对照IgG诱导更多血小板黏附/血栓形成,达那肝素和阿加曲班以及肝素可有效抑制该促凝活性。作者指出需临床验证后方可给出VITT抗凝药物选择建议。

要点

  • VITT患者IgG较健康对照IgG诱导更多黏附血小板/血栓形成。
  • 达那肝素和阿加曲班以及肝素可有效抑制VITT IgG的促凝活性。
  • 肝素和达那肝素可解离已形成的PF4/IgG复合物。

核心结论

  • 带负电荷的抗凝药物可破坏VITT抗体/PF4相互作用,可能成为减少VITT中抗体介导并发症的途径。
  • 在就VITT患者抗凝药物选择提出推荐之前,结果需在临床环境中证实。

研究设计与样本

  • 研究采用体外血流模型分析血栓形成,并用体外实验分析抗体结合和血小板活化。
  • 研究检测了肝素、达那肝素、磺达肝癸钠和阿加曲班与VITT抗体/PF4复合物的相互作用。

主要发现

  • VITT患者IgG较健康对照IgG诱导增加的黏附血小板/血栓形成。
  • 在该体外血流模型中,达那肝素和阿加曲班以及肝素有效抑制VITT IgG的促凝活性。
  • 肝素和达那肝素不仅抑制IgG与PF4结合,还能有效解离预先形成的PF4/IgG复合物。
  • 磺达肝癸钠减少体外促凝血小板生成和血栓形成,但不影响血小板聚集。
  • 阿加曲班对促凝血小板和聚集无影响,但显著抑制VITT介导的血栓形成。

临床怎么用

  • 当前指南建议使用非肝素抗凝药物治疗VITT患者。
  • 作者指出带负电荷的抗凝药物可破坏VITT抗体/PF4相互作用,可能作为减少VITT中抗体介导并发症的途径。
  • 作者指出在就VITT患者抗凝药物选择提出推荐之前,结果需在临床环境中证实。

局限性

  • 作者指出在就VITT患者抗凝药物选择提出推荐之前,结果需在临床环境中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Life-threatening thrombotic events at unusual sites have been reported after vector-based vaccinations against severe acute respiratory syndrome coronavirus 2. This phenomenon is now termed vaccine-induced immune thrombotic thrombocytopenia (VITT). The pathophysiology of VITT is similar to that of heparin-induced thrombocytopenia (HIT) and is associated with platelet-activating antibodies (Abs) against platelet factor 4 (PF4). Therefore, current guidelines suggest nonheparin anticoagulants to treat VITT patients. In this study, we investigated the interactions of heparin, danaparoid, fondaparinux, and argatroban with VITT-Ab/PF4 complexes using an ex vivo model for thrombus formation as well as in vitro assays to analyze Ab binding and platelet activation. We found that immunoglobulin Gs (IgGs) from VITT patients induce increased adherent platelets/thrombus formation in comparison with IgGs from healthy controls. In this ex vivo flow-based model, the procoagulant activity of VITT IgGs was effectively inhibited with danaparoid and argatroban but also by heparin. Interestingly, heparin and danaparoid not only inhibited IgG binding to PF4 but were also able to effectively dissociate the preformed PF4/IgG complexes. Fondaparinux reduced the in vitro generation of procoagulant platelets and thrombus formation; however, it did not affect platelet aggregation. In contrast, argatroban showed no effect on procoagulant platelets and aggregation but significantly inhibited VITT-mediated thrombus formation. Taken together, our data indicate that negatively charged anticoagulants can disrupt VITT-Ab/PF4 interactions, which might serve as an approach to reduce Ab-mediated complications in VITT. Our results should be confirmed, however, in a clinical setting before a recommendation regarding the selection of anticoagulants in VITT patients could be made.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Singh A, Toma F, Uzun G, et al. The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood. 2022. PMID: 35679071. doi:10.1182/blood.2021013839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。